AstraZeneca Annual Report and Form 20-F Information 2008

Other legal notices

Trade marks

Trade marks of the AstraZeneca group of companies appear throughout this document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trade marks of the AstraZeneca group of companies. Trade marks of companies other than AstraZeneca appear with a ® or ™ sign and include: Abraxane®, a registered trade mark of Abraxis BioScience, LLC.; Advair Diskus™, a trade mark of GlaxoSmithKline group of companies; Aspirin™, a trade mark of Bayer AG; Avastin™, a trade mark of Genentech, Inc.; BiTE™, a trade mark of Micromet AG; Cubicin™, a trade mark of Cubist Pharmaceuticals, Inc.; Captisol™, a trade mark of CyDex Pharmaceuticals Inc.; CytoFab™, a trade mark of Protherics, Inc.; Enbrel™, a trade mark of Amgen group of companies; EvaluatePharma®, a trade mark of Evaluate PLC; Herceptin™, a trade mark of Genentech, Inc.; Humira™, a trade mark of Abbott Biotechnology Ltd; Lean Sigma™, a trade mark of Smallpiece Enterprises Limited; Lipitor™, a trade mark of Pfizer Ireland Pharmaceuticals; Onglyza™, a trade mark of the Bristol-Myers Squibb Company; Prinivil™, a trade mark of Merck & Co., Inc.; Remicade™, a trade mark of Centocor, Inc.; Seretide™, a trade mark of GlaxoSmithKline group of companies; Taxotere™, a trade mark of Aventis Pharma SA; TriCor™, a trade mark of Fournier Industrie et Santé; Trilipix™, a trade mark of Abbott Laboratories; Zocor™, a trade mark of Merck & Co., Inc.; and Zyprexa™, a trade mark of Eli Lilly and Company.

Use of terms

In this Annual Report and Form 20-F Information, unless the context otherwise requires, ’AstraZeneca’, ’the Group’, ’we’, ’us’ and ’our’ refer to AstraZeneca PLC and its consolidated entities.

Statements of dates

Except as otherwise stated, references to days and/or months in this Annual Report and Form 20-F Information are references to days and/or months in 2008.

Statements of competitive position, growth rates and sales

In this Annual Report and Form 20-F Information, except as otherwise stated, market information regarding the position of our business or products relative to its or their competition is based upon published statistical sales data for the 12 months ended 30 September 2008 obtained from IMS Health, a leading supplier of statistical data to the pharmaceutical industry. For the US, dispensed new or total prescription data are taken from the IMS Health National Prescription Audit for the 12 months ended 31 December 2008. Except as otherwise stated, these market share and industry data from IMS Health have been derived by comparing our sales revenue to competitors’ and total market sales revenues for that period. Except as otherwise stated, growth rates and sales are given at constant exchange rates. For the purposes of this Annual Report and Form 20-F Information, unless otherwise stated references to the world pharmaceutical market or similar phrases are to 52 countries contained in IMS Health MIDAS Quantum database, which amounted to approximately 95% (in value) of the countries audited by IMS.

AstraZeneca websites

Information on or accessible through our websites, including astrazeneca.com, astrazenecaclinicaltrials.com, medimmune.com and cambridgeantibody.com, does not form part of this report.

External/third party websites

Information on or accessible through any third party or external website does not form part of this report.

Website design and production

Addison Corporate Marketing